Anglo Asian Mining Share Discussion Threads

[wanobi] 28/4/2020 09:14

wish I was Rb :-) LOL, cheers Wan :-)

[riggerbeautz] 28/4/2020 09:12

Anyone in HEMO from yesterday morning really ought to take some profit at least.

[goodgrief] 28/4/2020 08:59

Dated November 2016, Azerbaijan-focused miner Anglo Asian Mining Plc said its Gedabek gold, copper and silver mine was now hooked up to the national grid, which is expected to result in annual cost savings of around $2.3mln."The diesel electrical generators at site will be retired from service but kept as backup, which will de-risk the operation to power outages," he said.

[wanobi] 28/4/2020 08:45

4D - could be the ODX herd be moving their cash into it today,,, I wonder :-) Cheers Wan :-)

[wanobi] 28/4/2020 08:42

AAZ - I think it might just do that today MF :-) Cheers Wan :-)

[mad foetus] 28/4/2020 08:27

BUR up 27%, and still miles off where it would have been considered a screaming bargain a few months ago. Didn't top up earlier but am sure I bought some at 350 not long ago. DDDD trying to get above 60p, AVCT above £1, come on AAZ, come to the party!!!

[wanobi] 28/4/2020 08:27

4D - I doubt it jbe, Bumpa is watching it closely though, many thanx Bumpa,,, I think we'll know as without any bad news I can see a rapid rise once the seller has cleared there, but when that will be, who knows right now,,,, GLA Cheers Wan :-)

[wanobi] 28/4/2020 08:24

yep, well done ODR & KS & all others in ALTN,,,, I was also in it for a while,,,, my problem is I just cannot handle holding too many stocks at one time,,,,, got to get better at that Wan LOL,,,, 8 I'm happy with, when I get to 11 I just get dizzy with it all LOL LOL GLA Cheers Wan :-)

[homebrewruss] 28/4/2020 08:20

ODR, well done with ALTN. I was in ALTN until a couple of months back and then sold out with almost everything else in the folio.
More recently decided to take another gold position and was tossing up between ALTN and SRB (or mix of the two) and decided to go with SRB due to cash they will be generating this year, communication and plans for expansion.
Hoping for a slight pullback on ALTN post results though and might build a smaller position there.

[riggerbeautz] 28/4/2020 08:20

Nigerian most definitely! :( Chinese most probably.

HEMO there she blows. Lol

[jbe81] 28/4/2020 08:20

Is the seller done AT DDDD?

[bumpa33] 28/4/2020 08:18

Yep, Russian too Mr Roper, Chinese, Nigerian, anywhere ending in ‘stan’ etc etc!

[jbravo2] 28/4/2020 08:17

It really isn’t their biggest cost.
People are. By far.
We’re not going to see costs decline by anything like the degree the oil price has.

[onedayrodders] 28/4/2020 07:56

ALTN still in orbit mode.

Results imminent and not likely to be earth shattering because it's all about the forward looking statement post their recent ramp up of nice new impressive mining equipment and how that changes the numbers going forward.

IMHO

ODR

[gold finger 1] 28/4/2020 07:52

I think most people are unhappy about the way the MM's are treating our company with a stupid spread. When you look at greatland gold and they have a spread of just 2.3% compared to here at 7.69%.
No one is really unhappy with the management.
I can understand people not being happy with the share price right now, because even waiting for news,we have seen the gold price rise and the biggest expense for a mining company, oil half in price.

[wanobi] 28/4/2020 07:52

agreed Bumpa, added to cv19 watch list, let's see,,,,, nuts if it does rocket on that,,,, LOL Cheers Wan :-)

btw the first oil and gas producer in the list LOL LOL

[riggerbeautz] 28/4/2020 07:51

Morning Wan you’re welcome.

SIE frustration maybe, at trying to make himself heard ha

[mr roper] 28/4/2020 07:50

I know what you mean, bumpa. There was quite a few shockers back in the day. I made an exception for plus. I have a similar phobia on Russian stocks, only one rns away from a wtf moment.

[bumpa33] 28/4/2020 07:47

Unfortunately a deep mistrust of Israeli companies remains to this day, from the spate of frauds/junk listing back in the mid noughties.

ZEN - if that thing goes up on THAT RNS then we’re officially in the lunatic phase of all this cv-19 thing.

[wanobi] 28/4/2020 07:41

Great links Rb, just got through them both, the PM one - very interesting indeed, many thanx again for posting them, cheers Wan :-)

[mr roper] 28/4/2020 07:33

PLUs500 smacks it out the park with another top notch trading update.

[pogue] 28/4/2020 07:28

An article neatly summing up why ORPH is a candidate for the CV19 bingo game. It has other strings to its bow but the viral test side and the universal flu vaccine are probably the best bets in this environment. The chairman and very large share holder Cathal Freil's plan remains to sell the company this year at at least 3 times current share price, that's a longer story.

hxxps://www.vennlifesciences.com/inside-stories-of-coronavirus-battlers-aerogen-hibergene-open-orphan-and-nearform/

Open Orphan
Cathal Friel, the chairman of Open Orphan, calls hVivo his “lucky acquisition”. HVivo specialises in viral study models and testing the efficacy of vaccines. The company owns a 24-bedroom quarantine clinic in London.
The AIM-quoted Open Orphan bought hVivo “because it looked cheap”, says Friel. About £113m (€130m) has been invested in the clinic, viral testing models and a universal flu vaccine. While structured as a merger, Open Orphan in effect bought hVivo for £13m. It was an “unloved company” in an unfashionable corner of the pharma services sector, according to Friel — but not any more.

“In truth, in the past number of years there hasn’t been a lot of money spent on developing vaccines — it’s been all talk and no action,” he says. “In the past six weeks, suddenly, being a world leader in viral studies and testing has become a very interesting place.”

Last week Open Orphan announced its involvement in an antiviral treatment trial for Covid-19 with Russian pharma outfit Nearmedic International. It is in talks with eight pharma firms about using its facilities to mount a “human challenge” study on potential vaccine candidates. As such, it could play an integral part in bringing a vaccine to market quickly.

Normally, the efficacy of a vaccine candidate is tested in field studies, where the treatment and a placebo are given to thousands — or even tens of thousands — of people. Reseachers monitor those who get infected and how they react.

These phase III field studies are complex and time-consuming, and often the longest part of a vaccine’s development. With Covid-19, the focus of the health authorities and the public is to suppress the natural spread of the virus, which may frustrate the field study.

With a human challenge study, a small sample of people, perhaps 100 to 150 , are given the vaccine candidate or a placebo. All subjects are then infected with an attenuated strain of coronavirus a month later, and monitored in a quarantined environment for 10 days. Nir Eyal, director of the centre for population-level bioethics at Rutgers University in New Jersey, told Nature publication that human challenge studies could “greatly accelerate the time to approval and potential use” of a coronavirus vaccine.

The hVivo clinic has a virology laboratory and is one of only two such private facilities in Europe.

Friel said volunteers would be selected from the lowest-risk, healthiest cohorts. The clinic will have access to a full array of antiviral treatments, if necessary. “Over a three-month period, we can have 140 patients tested,” says Friel.

An ethical concern exists about challenging humans with even a weakened strain of a potentially deadly virus. Eyal says society lets “humans volunteer to do risky things” all the time. “We let people volunteer to be emergency medical services during this period. That significantly elevates their risk of getting infected.”

HVivo placed the call for volunteers for a coronavirus trial on its flucamp.com site on March 4. It has received 54,000 replies. “On a normal week we might get 20 to 40 volunteers,” says Friel. Volunteers get £3,500, but Friel says the motivation is not monetary. “It’s almost like contributing to the war effort.

[wanobi] 28/4/2020 07:13

yep, ODX to rocket again today :-) LOL,,, GLA Holders, cheers Wan :-)

[pogue] 28/4/2020 07:11

Eyes down Pharma Bingo call Omega (ODX) supply agreement RNS


RNS Number : 0470L
Omega Diagnostics Group PLC
28 April 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
VISITECT(R) CD4 Advanced Disease
Supply Agreement with Clinton Health Access Initiative, Inc.
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases, food intolerance and allergy testing, announces that it has signed a supply agreement ("Agreement") with Clinton Health Access Initiative, Inc. ("CHAI")(1) .
The objective of the Agreement is to accelerate access to Omega's VISITECT(R) CD4 Advanced Disease rapid test(2) in low-income countries, lower-middle income countries and upper-middle income countries (together "Eligible Countries") as classified by the World Bank. The VISITECT(R) CD4 Advanced Disease Test is the only currently available handheld lateral flow point of care test for identifying patients with advanced HIV who are at risk of potentially life-threatening opportunistic infections.
The Agreement runs until 31 December 2021, during which time CHAI, with support from Unitaid(3) , will procure up to a maximum of 500,000 VISITECT(R) CD4 Advanced Disease tests. Within 14 days of signing the Agreement, CHAI will place an initial purchase order for 100,000 tests with delivery dependent upon demand being confirmed by certain Eligible Countries. We expect demand to be confirmed by Eligible Countries later this quarter with shipment to follow thereafter.
The supply of VISITECT(R) CD4 Advanced Disease tests under the Agreement will help to inform Eligible Countries with national implementation planning to support routine use of the test.
Colin King, CEO of Omega commented: "We are pleased that Omega has been able to enter into this supply agreement with CHAI, who have been very supportive towards accelerating the availability of our VISITECT(R) CD4 Advanced Disease. This test will help support the healthcare needs of the many people in those countries that are most in need. "
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
(1) The Clinton Health Access Initiative, Inc. (CHAI) is a global health organisation committed to saving lives. CHAI works with partners to strengthen the capabilities of governments and the private sector to create and sustain high-quality health systems.
(2) VISITECT(R) CD4 Advanced Disease is a rapid, semi-quantitative lateral flow assay for the estimation of CD4 protein on the surface of CD4+ T cells in human whole blood that indicates whether the level is above or below 200 cells/L. It can be used in decentralised settings at the point-of-care or primary healthcare level, identifying those at risk of Opportunistic Infections and supporting diagnostic decision-making, particularly for patients living with advanced HIV disease.
(3) Unitaid is an international development agency that invests in innovations to prevent, diagnose and treat diseases including HIV/AIDS, hepatitis C, cervical cancer, tuberculosis and malaria more quickly, affordably and effectively. A growing number of Unitaid's programs address more than one disease, maximising the effectiveness of health systems.

[mad foetus] 28/4/2020 07:07

BUR results today. On the face of it, last year was quiet (which they have already told us) but the first few months of this year look incredible. But the figures are never easy to understand so I'm looking at the full report.